Wells’ criteria for pulmonary embolism (PE)
Authored by Patient infomatics teamOriginally published 8 Feb 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Wells’ criteria for pulmonary embolism is a clinical prediction rule used to estimate the pre-test probability of PE in patients presenting with symptoms suggestive of venous thromboembolism.
The score supports diagnostic decision-making by stratifying patients into likelihood categories and guiding the appropriate use of D-dimer testing and imaging.
Clinical context and use
Wells’ criteria for PE is used in primary care, emergency departments, and hospital settings when assessing patients with symptoms such as acute onset breathlessness, pleuritic chest pain, haemoptysis, syncope, or unexplained tachycardia.
Its primary role is to estimate the probability of PE before investigation, helping clinicians decide whether PE can be ruled out using D-dimer testing or whether immediate imaging is required.
The score is most appropriate for patients with suspected acute PE and should be applied before diagnostic testing where possible.
Components of Wells’ criteria for PE
Points are assigned for the following clinical features:
Clinical signs of deep vein thrombosis, such as leg swelling and pain with palpation, score 3 points.
Pulmonary embolism judged to be the most likely diagnosis scores 3 points.
Heart rate greater than 100 beats per minute scores 1.5 points.
Immobilisation for more than 3 days or surgery within the previous 4 weeks scores 1.5 points.
Previous documented DVT or PE scores 1.5 points.
Haemoptysis scores 1 point.
Active cancer, defined as treatment ongoing, within the previous 6 months, or palliative, scores 1 point.
The total score reflects the estimated clinical probability of PE.
Scoring and interpretation
Wells’ criteria for PE can be interpreted using either a three-level or two-level model.
In the traditional three-level model:
A score of 0–1 indicates low probability.
A score of 2–6 indicates moderate probability.
A score of more than 6 indicates high probability.
In the simplified two-level model, which is commonly used in UK practice:
A score of 4 points or fewer indicates PE unlikely.
A score of more than 4 points indicates PE likely.
Local diagnostic pathways should be followed when applying either model.
Role in diagnostic pathways
Wells’ criteria is typically used as the first step in a structured PE assessment pathway.
In patients classified as PE unlikely, a negative D-dimer test may be sufficient to safely exclude PE without the need for imaging. In patients classified as PE likely, or with a positive D-dimer, definitive imaging such as CT pulmonary angiography is usually indicated.
The score helps reduce unnecessary imaging while maintaining diagnostic safety.
Evidence base
Wells’ criteria for PE was developed and validated in outpatient and emergency department populations and has been shown to safely reduce imaging when combined with D-dimer testing.
It remains one of the most widely used clinical prediction rules for suspected PE and is incorporated into national and international diagnostic guidelines.
Limitations and clinical judgement
Wells’ criteria does not diagnose PE and should not be used in isolation.
Its accuracy may be reduced in certain populations, including:
Hospital inpatients.
Pregnant patients.
Patients already receiving anticoagulation.
Patients with recurrent PE.
Clinical judgement remains essential, particularly in patients who are haemodynamically unstable or have red flag features such as syncope, hypoxia, or circulatory compromise.
Practical use in consultation
Using Wells’ criteria provides a structured and reproducible approach to assessing suspected PE. Documenting the score can support clinical reasoning, guide investigation, and improve communication between clinicians.
Clear safety-netting and escalation advice should be provided, particularly when PE is considered unlikely but symptoms persist or worsen.
Patient picks for Cardiovascular disease

Professional
Pulmonary embolism
PERC Rule for Pulmonary Embolism; MD CALC, 2020 59728 : MD CALC PERC Rule for Pulmonary Embolism If PE is suspected, use the two-level PE Wells' score to estimate the clinical probability of PE (see below). Offer patients in whom PE is suspected and with a likely two-level PE Wells' score (more than 4 points) an immediate computerised tomography.
by Dr Doug McKechnie, MRCGP

Professional
409 - Primary Care Bulletin: NHS Updates for 8 October 2026
Introduction This article summarises the NHS England Primary Care Bulletin for 8 October 2026, the weekly email update for teams in general practice, dentistry, community pharmacy, and optometry. Summary of main themes This week’s bulletin highlights important updates related to coding appointments for clinically urgent patients, new vaccination.
by Thomas Andrew Porteus, MBCS

Professional
Field Safety Notices for October 2026
Field Safety Notices for October 2026 Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monit... Patient.info republishes MHRA alerts and recalls so that this information.
by Medicines and Healthcare products Regulatory Agency (MHRA)
A%2F42/og.png)
Professional
Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42
Norgine Pharmaceuticals Limited is recalling the batches listed in the table due to risk of particulate matter being present in the product identified during routine stability investigations. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for.
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
Pulmonary hypertension
Pulmonary hypertension (PH) is an increase in mean pulmonary arterial pressure (PAP), which can be caused by or associated with a wide variety of conditions. Definitions Humbert M, Kovacs G, Hoeper MM, et al; 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi:.
by Dr Toni Hazell, FRCGP

Professional
Pericardial effusion
Adler Y, Charron P, Imazio M, et al; 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Epub 2015 Aug 29. 49562 : 2015 ESC.
by Dr Toni Hazell, FRCGP
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
More in cardiovascular disease
- Brain natriuretic peptide
- Buerger's disease
- Cardiac transplant
- Cardiac-type chest pain presenting in primary care
- Cerebrovascular events
- CHA₂DS₂-VASc score
- Chronic pericarditis
- Complications of acute myocardial infarction
- Diabetic foot
- Ebstein's anomaly
- Endocardial fibroelastosis
- Fat embolism syndrome
- Fluid overload
- Flying with medical conditions
- Hypertension
- Hypertension treatment
- Hypertensive emergencies
- Inserting temporary pacemakers
- Takayasu's arteritis
- Venous thromboembolism in pregnancy


